JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, inclu…
Biotechnology
CN, Shanghai [HQ]
Cash Flow Statement
6 Sheets · From 2023 to 2018Configuration
In Million CNY. Margins, Growth Rates In %
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Cash Flow (OCF) | -106.00 | -188.00 | -261.00 | -561.00 | -536.00 | -398.00 | |
| Operating Cash (Net) | -106.00 | -188.00 | -261.00 | -561.00 | -536.00 | -398.00 | |
| Accounts Receivable | - - | - - | - - | - - | -5.00 | 5.00 | |
| Accounts Payable | - - | - - | - - | - - | 11.00 | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | |
| Change | - - | -18.00 | - - | -28.00 | -14.00 | 3.00 | |
| Other WC | - - | -18.00 | 17.00 | 78.00 | -11.00 | -7.00 | |
| Investing Activities | |||||||
| Used Cash (Net) | -44.00 | -117.00 | -91.00 | -137.00 | -124.00 | 9.00 | |
| Capital Expenditure | -44.00 | -101.00 | -124.00 | -73.00 | -76.00 | -14.00 | |
| Purchases of Investments | - - | - - | - - | - - | -23.00 | - - | |
| Sale/Maturity of Investment | - - | - - | - - | - - | - - | - - | |
| Property, Plant, Equipment (P&PE) | -44.00 | -101.00 | -124.00 | -73.00 | -76.00 | -14.00 | |
| Acquisitions (Net) | - - | - - | 45.00 | - - | - - | - - | |
| Other Investing Activities | - - | -15.00 | -12.00 | -64.00 | -23.00 | 22.00 | |
| Financing Activities | |||||||
| Used Cash (Net) | -249.00 | -414.00 | -2,859.00 | -30.00 | -112.00 | - - | |
| Debt Repayment | -2.00 | -45.00 | -11.00 | -13.00 | -115.00 | -27.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | |
| Issued | - - | - - | 2,140.00 | - - | - - | - - | |
| Repurchased | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 252.00 | 459.00 | 731.00 | -18.00 | 228.00 | -12.00 | |
| Cash Balances | |||||||
| Begin of Period | 21.00 | 133.00 | 254.00 | 2,630.00 | 1,834.00 | 1,383.00 | |
| End of Period | 133.00 | 254.00 | 2,630.00 | 1,834.00 | 1,383.00 | 1,005.00 | |
| Change | 112.00 | 121.00 | 2,375.00 | -796.00 | -451.00 | -377.00 | |
| Non-Cash Balances | |||||||
| Depreciation and Amortization | 5.00 | 17.00 | 23.00 | 46.00 | 81.00 | 99.00 | |
| Stock Based Compensation | - - | 15.00 | 134.00 | 89.00 | 82.00 | 34.00 | |
| Other | 161.00 | 427.00 | 1,379.00 | 94.00 | 228.00 | -21.00 | |
| Highlighted metrics | |||||||
| Free Cash Flow (FCF) | -150.00 | -290.00 | -385.00 | -634.00 | -613.00 | -412.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | -682.00 | -116.00 | 182.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||
| Forex Effect on Cash | 13.00 | 13.00 | -130.00 | -67.00 | 97.00 | 10.00 |